Followers | 325 |
Posts | 20140 |
Boards Moderated | 5 |
Alias Born | 12/15/2012 |
Tuesday, January 31, 2017 4:49:12 PM
http://www.protextm.co/investors
The Company is actively engaged in the research and clinical testing of “bioceutical” products—all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. Our initial product, Phytofare® Catechin Complex, has been clinically proven to have 10 times greater bioavailability over generic catechin extracts. Commencing early 2017, we will be conducting a human clinical trial to determine the effectiveness of Phytofare® in regulating blood sugar levels in diabetics. The trial will be conducted in the island country of Mauritius which has the highest per capita incidence of diabetes in the world. Assuming a favorable result, we anticipate having a product market ready by the end of 2017 and eventually filing for product claims with the US Food and Drug Administration.
We are majority-owned by Plandaí Biotechnology, Inc. (OTCQB: PLPL), a London-based holding company that controls over 8,000 acres of tea estate in the province of Mpumalanga, South Africa, and owns a 100,000 square foot manufacturing facility that produces Phytofare®.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM